Areas of Interest Main Article

Daiichi Sankyo Partnering Areas of Interest

To fulfill our mission of contributing to the enrichment of quality of life worldwide through the creation and provision of innovative pharmaceuticals addressing diverse medical needs, we continue to seek partners that match our values, work ethic and commitment to patients. Daiichi Sankyo is interested in unique clinical-stage programs across all therapeutic areas with demonstrated proof of concept (POC) and therapeutic value as well as marketed products, as follows:

  • Novel mechanisms of action (MOAs) that address significant unmet needs
  • Late-stage/marketed products requiring strong commercial execution
  • For early stage opportunities (prior to POC), our primary focus areas for licensing opportunities are:
    • Cardiovascular and Metabolic Disorders
      • Obesity
        • Novel mechanisms to suppress appetite
        • Mechanisms to increase energy expenditure
      • Type 2 Diabetes
        • Improvement of insulin resistance
        • Improvement of diabetes complications such as vascular disorder & chronic kidney disease
      • Novel Approaches for the Treatment of the following Cardiovascular Diseases:
        • Peripheral arterial disease
        • Ischemic stroke
        • Acute and chronic heart failure
    • Oncology
      • Targets that control tumor proliferation, metastases or invasion
      • Pathways implicated in oncogene addiction, cancer metabolism or resistance
      • Immunotherapy targets that impact inhibitory, regulatory and/or effector cells
      • Novel epigenetic or cancer stem cell research
    • Frontier
      • Progressive (genetic) diseases with high lethality
      • Degenerative diseases in peripheral neuro-muscular systems
      • Diseases caused by defect of barrier function of epithelial cells
      • Vision loss from retinal degeneration; hearing loss from cochlear degeneration
      • Endolymphatic hydrops (Ménière's disease)
      • Fibrosis of lung, and gastrointestinal tissues (including pancreas)
      • Disintegration or abnormal remodeling of lung and GI barrier
      • Immune dysfunctions

Our Future Interests More Stories

Learn More

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.

read more ...